Apremilast in the treatment of psoriatic arthritis: a perspective review
Authors:
Open Access
- 20 January 2017
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 9 (2) , 45-53
Abstract
Apremilast is an orally-active small molecule which inhibits phosphodiesterase-4 (PDE4). Clinical trials have demonstrated its efficacy and safety in psoriatic arthritis (PsA) and psoriasis. Established therapeutic options have variable effectiveness across the different domains of psoriatic disease. Whilst biologic therapies have proven to be of significant benefit to many patients, not all patients respond, and others are not eligible or do not tolerate biologic therapy. We review the mechanism of action, pharmacokinetics and clinical trial data with regards to both efficacy and safety for apremilast and consider where this new treatment may be positioned in the treatment of PsA.Keywords
This publication has 32 references indexed in Scilit:
- Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trialThe Lancet, 2012
- Apremilast mechanism of action and application to psoriasis and psoriatic arthritisBiochemical Pharmacology, 2012
- Cardiovascular Risk in Patients with Psoriatic ArthritisInternational Journal of Rheumatology, 2012
- A randomized placebo-controlled trial of methotrexate in psoriatic arthritisRheumatology, 2012
- Disposition, metabolism and mass balance of [14C]apremilast following oral administrationXenobiotica, 2011
- Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritisArthritis Research & Therapy, 2010
- Treatment recommendations for psoriatic arthritisAnnals of the Rheumatic Diseases, 2009
- Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2005
- Psoriatic arthritis: epidemiology, clinical features, course, and outcomeAnnals of the Rheumatic Diseases, 2005
- PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalizationBiochemical Journal, 2003